Neurochemistry and Neuropharmacology
Author: Aylén Camila Nelson Mohr | Email: aylen.nelson@uner.edu.ar
Aylén C. Nelson Mohr1°, L. Teresita Tribbia1°, Paula B. González2°, Omar A. Vallejos3°, Natalia Sosa2°, Irene R.E. Taravini1°
1° Laboratorio de Neurobiología Experimental. LNE-ICTAER-UNER-CONICET, Gualeguaychú, Entre Ríos, Argentina
2° Laboratorio de Desarrollo y Mejoramiento de Alimentos de Calidad a partir de Recursos de Entre Ríos. DyMACRER-ICTAER-UNER-CONICET, Gualeguaychú, Entre Ríos, Argentina
3° Área Cromatografía de la Facultad de Bromatología. UNER
The development of abnormal involuntary movements (AIMs) or dyskinesias is a common complication in the pharmacological treatment of neurological and psychiatric disorders associated with abnormal basal ganglia function, such as Parkinson’s disease (PD) and schizophrenia (SCZ). Both L-DOPA-induced dyskinesias (LIDs) in PD and tardive dyskinesia (TD) in SCZ are often irreversible and more disabling than the underlying condition itself. Using neuromodulation as an innovative therapeutic approach for AIMs, the endocannabinoid system has emerged as a promising treatment strategy due to its role in the physiological neuromodulation of the basal ganglia in the movement control. Considering the health benefits offered by various bioactive compounds in cannabis, including cannabinoids, we aim to obtain an extract of Cannabis sativa (CS) from the Entre Rios province with a profile of bioactive compounds and properties unique to the cultivation region. We also plan to test its potential therapeutic effect in animal models of AIMs induced by L-DOPA and haloperidol (HAL). The emerging results of this project will aid determined whether treatment with Entre Rios CS extracts has therapeutic potential to prevent or attenuate the severity of LIDs and TD in animal models, and whether this effect is accompanied by modulation of the synaptic microstructure of striatal cells.